JPWO2022107853A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022107853A5
JPWO2022107853A5 JP2022563827A JP2022563827A JPWO2022107853A5 JP WO2022107853 A5 JPWO2022107853 A5 JP WO2022107853A5 JP 2022563827 A JP2022563827 A JP 2022563827A JP 2022563827 A JP2022563827 A JP 2022563827A JP WO2022107853 A5 JPWO2022107853 A5 JP WO2022107853A5
Authority
JP
Japan
Prior art keywords
agent according
diabetes
promoter
administered
hgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563827A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022107853A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/042463 external-priority patent/WO2022107853A1/ja
Publication of JPWO2022107853A1 publication Critical patent/JPWO2022107853A1/ja
Publication of JPWO2022107853A5 publication Critical patent/JPWO2022107853A5/ja
Pending legal-status Critical Current

Links

JP2022563827A 2020-11-19 2021-11-18 Pending JPWO2022107853A1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020192844 2020-11-19
JP2021145795 2021-09-07
PCT/JP2021/042463 WO2022107853A1 (ja) 2020-11-19 2021-11-18 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療

Publications (2)

Publication Number Publication Date
JPWO2022107853A1 JPWO2022107853A1 (https=) 2022-05-27
JPWO2022107853A5 true JPWO2022107853A5 (https=) 2023-10-24

Family

ID=81707991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563827A Pending JPWO2022107853A1 (https=) 2020-11-19 2021-11-18

Country Status (4)

Country Link
US (1) US20230414718A1 (https=)
EP (1) EP4249003A4 (https=)
JP (1) JPWO2022107853A1 (https=)
WO (1) WO2022107853A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6711495B1 (ja) 2019-05-27 2020-06-17 株式会社ナイスリー 車両用盗難防止装置
JP7040806B2 (ja) 2020-03-17 2022-03-23 株式会社オリンピア 遊技機

Similar Documents

Publication Publication Date Title
Lu et al. Comparison of COVID-19 induced respiratory failure and typical ARDS: similarities and differences
Cavalli et al. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure
JP2023166388A5 (https=)
JP2004533405A5 (https=)
JP2019523648A5 (https=)
JP7359519B2 (ja) ライノウイルス感染症の予防又は治療のための薬物
JP2020073536A5 (https=)
JP2018502579A5 (https=)
JP2021533801A5 (https=)
Brzoska et al. Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?
Tamayo et al. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass
JP2021500880A5 (https=)
JP2011522864A5 (https=)
JPWO2022107853A5 (https=)
JPWO2022186282A5 (https=)
Divangahi et al. Impact of IL-10 on diaphragmatic cytokine expression and contractility during Pseudomonas infection
Chou et al. In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles
Wollborn et al. Extracorporeal resuscitation with carbon monoxide improves renal function by targeting inflammatory pathways in cardiac arrest in pigs
Zhu et al. A Case Report of Mycoplasma pneumoniae-induced fulminant myocarditis in a 15-year-old male leading to cardiogenic shock and electrical storm
Wedemeyer et al. 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31
WO2022056897A1 (zh) 白细胞介素37与干扰素联用在治疗病毒感染中的应用
JP2024529170A5 (https=)
EP4179069A1 (en) Methods for treating acute respiratory inflammatory conditions and cytokine storm syndrome
Liu et al. Republished review: Gene therapy for ocular diseases
JP2022551911A5 (https=)